Table 4.
Clinical outcomes of patients with CDK4/6, CDKN2A/B aberrations (univariate analysis)
| Clinical outcomes | Aberrant CDK4/6, CDKN2A/B Month (range) | Normal CDK4/6, CDKN2A/B Month (range) | P-value* | Comment |
|---|---|---|---|---|
| Median time from diagnosis to metastasis (N = 280) | 17.0 (0–256.7) N = 50 |
24.2 (0–415.1) N = 230 |
0.20 | (a) |
| PFS for first line Therapy | ||||
| Median PFS for all first line therapy (N = 189) | 3.3 (0.6–39.0) N = 41 |
5.0 (0.5–61.0) N = 148 |
0.32 | (b) |
| Subgroup analysis of median PFS for first line therapy | ||||
| Platinum-containing regimen (N = 62) | 3.5 (0.6–11.0) N = 15 |
5.0 (1.0–34.0) N = 47 |
0.13 | (c) |
| 5-FU or capecitabine- containing regimen (N = 50) | 5.0 (0.6–11.0) N = 11 |
5.0 (0.8–21.0) N = 39 |
0.3 | (d) |
| Bevacizumab-containing regimen (N = 33) | 6.5 (2.0–39.0) N = 6 |
6.5 (1.0–34.0) N = 27 |
0.43 | |
| Taxane-containing regimen (N = 32) | 3.0 (0.6–39.0) N = 7 |
9.1 (1.0–38.7) N = 25 |
0.88 | (e) |
P-values are from log-rank test.
(a) Excluded patients with hematological malignancy (N = 21) and CNS tumors (N = 46).
(b) First line therapy referred to first line after metastatic or recurrent disease (N = 189). Excluded patients with hematological malignancy (N = 21). Neoadjuvant/adjuvant therapy was not included (N = 56). Chemotherapy was not initiated on 33 patients and 48 patients were not assessable for accurate PFS for first line therapy.
(c) Platinum-containing regimen (N = 62): Cisplatin (N = 20), carboplatin (N = 21) and oxaliplatin (N = 21).
(d) 5-FU or capecitabine-containing regimen (N = 50): 5-FU (N = 30) and capecitabine (N = 20)
(e) Taxane-containing regimen (N = 32): Paclitaxel (N = 22), docetaxel (N = 5) and abraxane (N = 5).